These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Design of Boron-Based Peptidomimetics Leads to Potent Inhibitors of Human ClpP and ClpXP

submitted on 30.11.2018, 21:03 and posted on 03.12.2018, 16:33 by Joanne Tan, Julie Jungberg Grouleff, Yulia Jitkova, Diego Diaz, Elizabeth Griffith, Wenjie Shao, Anastasia Bogdanchikova, Gennady Poda, Aaron Schimmer, Richard Lee, Andrei Yudin

Boronic acids have attracted the attention of synthetic and medicinal chemists due to boron’s ability to modulate enzyme function. Recently, we demonstrated that boron-containing amphoteric building blocks facilitate the discovery of bioactive aminoboronic acids. Herein, we have augmented this capability with a de novo library design and virtural screening platform modified for covalent ligands. This technique has allowed us to rapidly design and identify a series of α-aminoboronic acids as the first inhibitors of human ClpXP, which is responsible for the degradation of misfolded proteins.


Email Address of Submitting Author


University of Toronto



ORCID For Submitting Author


Declaration of Conflict of Interest

No conflict of interest.